CapVest recapitalises Curium in $7bn record deal targeting accelerated growth
Curium, a leading producer of radiopharmaceuticals, and global investment firm CapVest Partners (CapVest) have announced the recapitalisation of Curium via a new Continuation Vehicle (CV) that values Curium at circa $7bn, making this the largest transaction in nuclear medicine globally. The transaction elicited wide support from existing and new institutional investors across the US, Europe, the Middle East and APAC.…